These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 38390786)
1. Shifts in patient preference of third-line overactive bladder therapy after introduction of the implantable tibial nerve stimulator. Kapur A; Aalami Harandi A; Hartman-Kenzler J; Kim J Neurourol Urodyn; 2024 Apr; 43(4):959-966. PubMed ID: 38390786 [TBL] [Abstract][Full Text] [Related]
2. An analysis of factors that influence patient preference of third-line therapy for overactive bladder. Kapur A; Harandi AA; Cohen T; Ruan H; Dabrowski C; Anderson R; Hwang K; Lee E; Weissbart S; Kim J Neurourol Urodyn; 2022 Nov; 41(8):1906-1913. PubMed ID: 36104866 [TBL] [Abstract][Full Text] [Related]
3. Patient preferences for treating refractory overactive bladder in the UK. Hashim H; Beusterien K; Bridges JF; Amos K; Cardozo L Int Urol Nephrol; 2015 Oct; 47(10):1619-27. PubMed ID: 26347077 [TBL] [Abstract][Full Text] [Related]
4. Trends in minimally invasive surgical therapies for overactive bladder management in Australia. Ng Hung Shin PB; Rhee H; Chung E Low Urin Tract Symptoms; 2022 Nov; 14(6):427-433. PubMed ID: 36098437 [TBL] [Abstract][Full Text] [Related]
5. Determining patient preferences in the treatment of medication-refractory overactive bladder. Speed J; Welk B; Comiter C; Elliott C Neurourol Urodyn; 2023 Feb; 42(2):419-426. PubMed ID: 36480150 [TBL] [Abstract][Full Text] [Related]
6. Contemporary Patterns of Third-line Treatments for Privately Insured Individuals With Overactive Bladder in the United States. Jiang J; Patil D; Traore EJ; Hammett J; Filson CP Urology; 2020 Aug; 142():87-93. PubMed ID: 32437771 [TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy of Neuromodulation Technologies for Overactive Bladder in Adults: A Network Meta-Analysis of Randomized Controlled Trials. Huang J; Fan Y; Zhao K; Yang C; Zhao Z; Chen Y; Yang J; Wang T; Qu Y Neuromodulation; 2023 Dec; 26(8):1535-1548. PubMed ID: 35989159 [TBL] [Abstract][Full Text] [Related]
8. What Is the Role of Additional Pharmacotherapy and Neuromodulation in Patients with Marginal Benefit from Botulinum Toxin Injection? Zahner PM; Giusto LL; Goldman HB Curr Urol Rep; 2018 Sep; 19(11):91. PubMed ID: 30196438 [TBL] [Abstract][Full Text] [Related]
9. A single-blind, randomized controlled trial to evaluate the effectiveness of transcutaneous tibial nerve stimulation (TTNS) in Overactive Bladder symptoms in women responders to percutaneous tibial nerve stimulation (PTNS). Martin-Garcia M; Crampton J Physiotherapy; 2019 Dec; 105(4):469-475. PubMed ID: 30862384 [TBL] [Abstract][Full Text] [Related]
10. How can we better manage drug-resistant OAB/DO? ICI-RS 2018. Chermansky C; Schurch B; Rahnama'i MS; Averbeck MA; Malde S; Mancini V; Valentini F; Sahai A Neurourol Urodyn; 2019 Dec; 38 Suppl 5():S46-S55. PubMed ID: 31821628 [TBL] [Abstract][Full Text] [Related]
12. Predictors of successful percutaneous tibial nerve stimulation (PTNS) in the treatment of overactive bladder syndrome. Rostaminia G; Chang C; Pincus JB; Sand PK; Goldberg RP Int Urogynecol J; 2019 Oct; 30(10):1735-1745. PubMed ID: 30498931 [TBL] [Abstract][Full Text] [Related]
13. Development of an implant technique and early experience using a novel implantable pulse generator with a quadripolar electrode array at the tibial nerve for refractory overactive bladder. Sirls LT; Schonhoff A; Waldvogel A; Peters KM Neurourol Urodyn; 2023 Feb; 42(2):427-435. PubMed ID: 36573835 [TBL] [Abstract][Full Text] [Related]
14. Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation. Sherif H; Khalil M; Omar R Can J Urol; 2017 Jun; 24(3):8838-8846. PubMed ID: 28646940 [TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States. Kraus SR; Shiozawa A; Szabo SM; Qian C; Rogula B; Hairston J Neurourol Urodyn; 2020 Nov; 39(8):2206-2222. PubMed ID: 32827230 [TBL] [Abstract][Full Text] [Related]
16. Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis. Lo CW; Wu MY; Yang SS; Jaw FS; Chang SJ Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085542 [TBL] [Abstract][Full Text] [Related]